Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 210-217

  Zhao, Min ^a   Tang, Su Ni ^a   Marsh, Justin L ^b   Shankar, Sharmila ^a   Srivastava, Rakesh K ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Akt; Cancer prevention; Ellagic acid; Notch; Pancreatic cancer; Sonic hedgehog

Indexed keywords

CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; CYCLOOXYGENASE 2; ELLAGIC ACID; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; NEUTROPHIL COLLAGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PROTEIN BCL 2; PROTEIN HEY1; PROTEIN KINASE B; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE PRODUCT; GENE TARGETING; HUMAN; HUMAN CELL; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION;

AKT; CANCER PREVENTION; ELLAGIC ACID; NOTCH; PANCREATIC CANCER; SONIC HEDGEHOG;

ANGIOGENIC PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ELLAGIC ACID; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ERINACEIDAE; GASTROPODA; MUS; MUS MUSCULUS;

EID: 84880513749     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.009     Document Type: Article

References (81)

1. Warshaw A.L. Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 1992, 326:455-465.
2. Magee C.J., Ghaneh P., Neoptolemos J.P. Surgical and medical therapy for pancreatic carcinoma. Best Pract. Res. Clin. Gastroenterol. 2002, 16:435-455.
3. Li D. Molecular epidemiology of pancreatic cancer. Cancer J. 2001, 7:259-265.
4. Gold E.B., Goldin S.B. Epidemiology of and risk factors for pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998, 7:67-91.
5. Vattem D.A., Ghaedian R., Shetty K. Enhancing health benefits of berries through phenolic antioxidant enrichment: focus on cranberry. Asia Pac. J. Clin. Nutr. 2005, 14:120-130.
6. Thresiamma K.C., Kuttan R. Inhibition of liver fibrosis by ellagic acid. Indian J. Physiol. Pharmacol. 1996, 40:363-366.
7. Nijhoff W.A., Peters W.H. Quantification of induction of rat oesophageal, gastric and pancreatic glutathione and glutathione S-transferases by dietary anticarcinogens. Carcinogenesis 1994, 15:1769-1772.
8. Umesalma S., Sudhandiran G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur. J. Pharmacol. 2011, 660:249-258.
9. Edderkaoui M., Odinokova I., Ohno I., Gukovsky I., Go V.L., Pandol S.J., et al. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J. Gastroenterol. 2008, 14:3672-3680.
10. Feick P., Gerloff A., Singer M.V. Effect of non-alcoholic compounds of alcoholic drinks on the pancreas. Pancreatology 2007, 7:124-130.
11. Gerloff A., Singer M.V., Feick P. Beer and its non-alcoholic compounds: role in pancreatic exocrine secretion, alcoholic pancreatitis and pancreatic carcinoma. Int. J. Environ. Res. Public Health 2010, 7:1093-1104.
12. Rajakangas J., Misikangas M., Paivarinta E., Mutanen M. Chemoprevention by white currant is mediated by the reduction of nuclear beta-catenin and NF-kappaB levels in Min mice adenomas. Eur. J. Nutr. 2008, 47:115-122.
13. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
14. Hockel M., Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 2001, 28:36-41.
15. Le Q.T., Denko N.C., Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metast. Rev. 2004, 23:293-310.
16. Semenza G.L. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr. Pharm. Des. 2009, 15:3839-3843.
17. Saqui-Salces M., Merchant J.L. Hedgehog signaling and gastrointestinal cancer. Biochim. Biophys. Acta 2010, 1803:786-795.
18. Lum L., Beachy P.A. The Hedgehog response network: sensors, switches, and routers. Science 2004, 304:1755-1759.
19. Rohatgi R., Scott M.P. Patching the gaps in Hedgehog signalling. Nat. Cell Biol. 2007, 9:1005-1009.
20. Kinzler K.W., Ruppert J.M., Bigner S.H., Vogelstein B. The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 1988, 332:371-374.
21. Arlt A., Muerkoster S.S., Schafer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2010.
22. Kennedy A.L., Adams P.D., Morton J.P. Ras, PI3K/Akt and senescence: paradoxes provide clues for pancreatic cancer therapy. Small GTPases 2011, 2:264-267.
23. Hill R., Calvopina J.H., Kim C., Wang Y., Dawson D.W., Donahue T.R., et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res. 2010, 70:7114-7124.
24. Shankar S., Nall D., Tang S.N., Meeker D., Passarini J., Sharma J., et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS ONE 2011, 6:e16530.
25. Ma Y.C., Shi C., Zhang Y.N., Wang L.G., Liu H., Jia H.T., et al. The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells. PLoS ONE 2012, 7:e33414.
26. Mann C.D., Bastianpillai C., Neal C.P., Masood M.M., Jones D.J., Teichert F., et al. Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma. PLoS ONE 2012, 7:e51119.
27. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 2012, 727:305-319.
28. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell Mol. Life Sci. 2007, 64:2746-2762.
29. Afelik S., Qu X., Hasrouni E., Bukys M.A., Deering T., Nieuwoudt S., et al. Notch-mediated patterning and cell fate allocation of pancreatic progenitor cells. Development 2012, 139:1744-1753.
30. Kopinke D., Brailsford M., Pan F.C., Magnuson M.A., Wright C.V., Murtaugh L.C. Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreas. Dev. Biol. 2012, 362:57-64.
31. De La O.J., Murtaugh L.C. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. Cell Cycle 2009, 8:1860-1864.
32. Harris M.H., Thompson C.B. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000, 7:1182-1191.
33. Vander Heiden M.G., Thompson C.B. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis?. Nat. Cell Biol. 1999, 1. E209-16.
34. Shankar S., Chen X., Srivastava R.K. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2005, 62:165-186.
35. Tang S.N., Fu J., Nall D., Rodova M., Shankar S., Srivastava R.K. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int. J. Cancer 2012, 131:30-40.
36. Shankar S., Ganapathy S., Hingorani S.R., Srivastava R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front. Biosci. 2008, 13:440-452.
37. Basanez G., Soane L., Hardwick J.M. A new view of the lethal apoptotic pore. PLoS Biol. 2012, 10:e1001399.
38. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
39. Harada H., Grant S. Apoptosis regulators. Rev. Clin. Exp. Hematol. 2003, 7:117-138.
40. Hill R., Li Y., Tran L.M., Dry S., Calvopina J.H., Garcia A., et al. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol. Cancer Ther. 2012, 11:2127-2137.
41. Folkman J. Angiogenesis and proteins of the hemostatic system. J. Thromb. Haemost. 2003, 1:1681-1682.
42. Fernando R.I., Castillo M.D., Litzinger M., Hamilton D.H., Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011, 71:5296-5306.
43. Palena C., Hamilton D.H., Fernando R.I. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol. 2012, 8:713-722.
44. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 2006, 12:895-904.
45. Kraljevic Pavelic S., Sedic M., Bosnjak H., Spaventi S., Pavelic K. Metastasis: new perspectives on an old problem. Mol. Cancer 2011, 10:22.
46. Metastasis Mc.Carthy.N. Route master. Nat. Rev. Cancer 2009, 9:610.
47. Metastasis Mc.Carthy.N. Influencing bad behaviour. Nat. Rev. Cancer 2009, 9:609.
48. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
49. Altomare D.A., Tanno S., De Rienzo A., Klein-Szanto A.J., Tanno S., Skele K.L., et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J. Cell Biochem. 2003, 88:470-476.
50. Maitra A., Hruban R.H. A new mouse model of pancreatic cancer: PTEN gets its Akt together. Cancer Cell 2005, 8:171-172.
51. Jenkins D. Hedgehog signalling: emerging evidence for non-canonical pathways. Cell Signal. 2009, 21:1023-1034.
52. Fu J., Rodova M., Roy S.K., Sharma J., Singh K.P., Srivastava R.K., et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013, 330:22-32.
53. Singh B.N., Fu J., Srivastava R.K., Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS ONE 2011, 6:e27306.
54. Yabuuchi S., Pai S.G., Campbell N.R., Wilde R.D., Oliveira E.D., Korangath P., et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett. 2013.
55. J.M. Bailey, S.D. Leach, Signaling pathways mediating epithelial- mesenchymal crosstalk in pancreatic cancer: Hedgehog, Notch and TGFbeta. In: P.J. Grippo, H.G. Munshi (Eds.), Pancreatic Cancer and Tumor Microenvironment, Transworld Research Network, Trivandrum (India), 2012.
56. Krausch M., Kroepil F., Lehwald N., Lachenmayer A., Schott M., Anlauf M., et al. Notch 1 tumor expression is lacking in highly proliferative pancreatic neuroendocrine tumors. Endocrine 2012.
57. Duong H.Q., Kim H.J., Kang H.J., Seong Y.S., Bae I. ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncol. Rep. 2012, 27:182-188.
58. Fritz S., Fernandez-del Castillo C., Iafrate A.J., Mino-Kenudson M., Neyhard N., LaFemina J., et al. Novel xenograft and cell line derived from an invasive intraductal papillary mucinous neoplasm of the pancreas give new insights into molecular mechanisms. Pancreas 2010, 39:308-314.
59. Nissim S., Idos G.E., Wu B. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas 2012, 41:1195-1205.
60. Nolan-Stevaux O., Lau J., Truitt M.L., Chu G.C., Hebrok M., Fernandez-Zapico M.E., et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23:24-36.
61. Lauth M., Toftgard R. Hedgehog signaling and pancreatic tumor development. Adv. Cancer Res. 2011, 110:1-17.
62. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
63. Li S.H., Fu J., Watkins D.N., Srivastava R.K., Shankar S. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol. Cell Biochem. 2013, 373:217-227.
64. Rodova M., Fu J., Watkins D.N., Srivastava R.K., Shankar S. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS ONE 2012, 7:e46083.
65. Tang S.N., Singh C., Nall D., Meeker D., Shankar S., Srivastava R.K. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J. Mol. Signal. 2010, 5:14.
66. Srivastava R.K., Tang S.N., Zhu W., Meeker D., Shankar S. Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front. Biosci. (Elite Ed.) 2011, 3:515-528.
67. Hao K., Tian X.D., Qin C.F., Xie X.H., Yang Y.M. Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. Oncol. Rep. 2013, 29:1124-1132.
68. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29:15-18.
69. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 9:677-684.
70. Hirota K., Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 2006, 59:15-26.
71. Fong G.H. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 2008, 11:121-140.
72. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 1996, 16:4604-4613.
73. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998, 17:3005-3015.
74. Al-Wadei H.A., Al-Wadei M.H., Ullah M.F., Schuller H.M. Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS ONE 2012, 7:e43376.
75. Hogendorf P., Durczynski A., Kumor A., Strzelczyk J. Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor - a single institution series. J. Invest. Surg.: Off. J. Acad. Surg. Res. 2012, 25:8-13.
76. Jamieson N.B., Carter C.R., McKay C.J., Oien K.A. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin. Cancer Res. 2011, 17:3316-3331.
77. Yao J., Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Med. Oncol. 2010, 27:1017-1022.
78. Acloque H., Adams M.S., Fishwick K., Bronner-Fraser M., Nieto M.A. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J. Clin. Invest. 2009, 119:1438-1449.
79. Brabletz T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 2012.
80. Sarkar F.H., Li Y., Wang Z., Kong D. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009, 64:489-500.
81. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.